Asian Value Stocks With Estimated Attractive Valuations

Recent developments in the Asian markets have been influenced by global economic uncertainties and rising oil prices, leading to increased volatility. Amid these fluctuations, investors are paying closer attention to value stocks, which can offer attractive valuations due to their potential for growth relative to their current market price.

Top 10 Undervalued Stocks Based On Cash Flows In Asia

Name	Current Price	Fair Value (Est)	Discount (Est)
Thai Credit Bank (SET:CREDIT)	THB22.90	THB45.74	49.9%
Smartsens Technology (Shanghai) (SHSE:688213)	CN¥108.69	CN¥215.98	49.7%
P&H Tech (KOSDAQ:A239890)	₩3110.00	₩6201.38	49.8%
PAL GROUP Holdings (TSE:2726)	¥1480.00	¥2915.17	49.2%
Nissei ASB Machine (TSE:6284)	¥7900.00	¥15783.35	49.9%
Natural Food International Holding (SEHK:1837)	HK$1.41	HK$2.80	49.6%
Kissei Pharmaceutical (TSE:4547)	¥3855.00	¥7679.17	49.8%
Kingnet Network (SZSE:002517)	CN¥15.57	CN¥30.58	49.1%
Henan Mingtai Al.IndustrialLtd (SHSE:601677)	CN¥14.11	CN¥28.12	49.8%
ENN Energy Holdings (SEHK:2688)	HK$49.38	HK$97.32	49.3%

Click here to see the full list of 184 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.

Here we highlight a subset of our preferred stocks from the screener.

Mega Lifesciences (SET:MEGA)

Overview: Mega Lifesciences Public Company Limited, along with its subsidiaries, is engaged in the manufacturing and sale of health food supplements, prescription pharmaceuticals, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods with a market cap of THB29.86 billion.

Operations: Mega Lifesciences generates revenue from its Brands segment with THB9.22 billion, Distribution at THB4.91 billion, and Original Equipment Manufacture (OEM) contributing THB377.82 million.

Estimated Discount To Fair Value: 23.2%

Mega Lifesciences is trading at THB34.25, significantly below its estimated future cash flow value of THB44.62, indicating it may be undervalued based on cash flows. Despite slower forecasted revenue growth of 4.9% annually compared to the Thai market's 8.2%, recent earnings reports show a positive trend with net income rising to THB1.12 billion for the first half of 2026 from THB840.75 million a year prior, reflecting robust operational performance amidst moderate growth expectations.

• Upon reviewing our latest growth report, Mega Lifesciences' projected financial performance appears quite optimistic.
• Click here to discover the nuances of Mega Lifesciences with our detailed financial health report.

Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357)

Overview: Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. operates in the biopharmaceutical industry, focusing on the research, development, and production of allergy diagnostics and treatments, with a market cap of CN¥10.99 billion.

Operations: The company generates revenue primarily from its Pharmaceutical Manufacturing segment, which amounts to CN¥1.12 billion.

Estimated Discount To Fair Value: 20.4%

Zhejiang Wolwo Bio-Pharmaceutical is trading at CNY 21, below its estimated future cash flow value of CNY 26.38, suggesting potential undervaluation. Recent earnings show growth in net income to CNY 391.29 million for the first nine months of 2026 from CNY 344.87 million a year ago, demonstrating solid financial performance despite slower revenue growth forecasts of 16.8% annually compared to the broader Chinese market's expectations.

• According our earnings growth report, there's an indication that Zhejiang Wolwo Bio-Pharmaceutical might be ready to expand.
• Dive into the specifics of Zhejiang Wolwo Bio-Pharmaceutical here with our thorough financial health report.

Kissei Pharmaceutical (TSE:4547)

Overview: Kissei Pharmaceutical Co., Ltd. is engaged in the research, development, manufacture, and sale of pharmaceutical products both in Japan and internationally, with a market cap of ¥159.51 billion.

Operations: The company's revenue segments include Pharmaceuticals at ¥78.73 billion, Information Service at ¥17.98 billion, Construction and Facility Maintenance at ¥6.87 billion, and Goods Sales amounting to ¥1.11 billion.

Estimated Discount To Fair Value: 49.8%

Kissei Pharmaceutical is trading at ¥3,855, significantly below its estimated future cash flow value of ¥7,679.17, highlighting potential undervaluation. Despite this, forecasted earnings are expected to decline by 3.3% annually over the next three years with low return on equity projections at 5.1%. Recent challenges include lowered earnings guidance due to decreased sales of TAVNEOS and regulatory scrutiny over its clinical trial data reliability for this key drug treatment for rare diseases.

• In light of our recent growth report, it seems possible that Kissei Pharmaceutical's financial performance will exceed current levels.
• Take a closer look at Kissei Pharmaceutical's balance sheet health here in our report.

Seize The Opportunity

• Dive into all 184 of the Undervalued Asian Stocks Based On Cash Flows we have identified here.
• Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com